• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Treatment of gastric precancerous lesions with Weiansan.
【24h】

Treatment of gastric precancerous lesions with Weiansan.

机译：胃安治疗胃癌前病变。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To observe the curative effect of Weiansan (WAS) on gastric precancerous lesions (GPL) and H pylori elimination. METHODS: Seventy-six patients with GPL were randomly divided into two groups: WAS group (n = 42) and Weifuchun (WFC) group (n = 34). The patients in the WAS group were administered 5 g WAS 3 times a day, and the patients in the WFC group took WFC (4 tablets) 3 times a day. To monitor inflammation of gastric mucosa, degree of glandular atrophy (GA), intestinal metaplasia (IM) and dysplasia, and H pylori infection, all patients underwent gastroscopy and biopsy with pathological examination before and after treatment. Fifty male Sprague-Dawley (SD) rats were used in animal experiments. Of these, 10 served as the control group (n = 10), 40 were given ranitidine combined with N-methyl-N(1)-nitro-N-nitrosoguanidine (MNNG) for 12 wk and divided into 4 groups randomly: model group (n = 10), high-dose WAS group (n = 10), low-dose WAS group (n = 10) and WFC group (n = 10). Twelve weeks later, allrats were killed and a 2 cm multiply 1 cm tissue was taken from the lesser curvature of the gastric antrum. H pylori infection was determined by the fast urease method. RESULTS: The curative effect in WAS groups was similar to that in WFC groups. There was no statistical difference in degree of GA, IM and dysplasia between WAS and WFC groups. The rate of H pylori infection in the model group (positiveegative: 9/1) was significantly higher than that in the control group (positiveegative: 1/9) (P < 0.01). H pylori elimination in the high-dose WAS group (positiveegative: 4/6) and low-dose WAS group (positiveegative: 6/4) was similar to that in the WFC group (positiveegative: 4/6) (P > 0.05). CONCLUSION: WAS improves clinical symptoms by suppressing GA, IM and dysplasia and eliminating H pylori.
机译：目的：观察Weiansan（WAS）对胃癌前病变（GPL）和幽门螺杆菌消除的疗效。方法：76例GPL患者被随机分为两组：WAS组（n = 42）和威孚春（WFC）组（n = 34）。 WAS组的患者每天3次服用5 g WAS，WFC组的患者每天3次服用WFC（4片）。为了监测胃粘膜的炎症，腺体萎缩程度（GA），肠化生（IM）和发育异常以及幽门螺杆菌感染，所有患者在治疗前后均进行了胃镜检查和活检，并进行了病理检查。五十只雄性Sprague-Dawley（SD）大鼠用于动物实验。其中10例为对照组（n = 10），40例给予雷尼替丁联合N-甲基-N（1）-硝基-N-亚硝基胍（MNNG），连续12周，随机分为4组：模型组（n = 10），高剂量WAS组（n = 10），低剂量WAS组（n = 10）和WFC组（n = 10）。十二周后，杀死所有大鼠，并从胃窦较小的弯曲处取出2厘米乘以1厘米的组织。幽门螺杆菌感染是通过快速尿素酶法确定的。结果：WAS组的疗效与WFC组相似。 WAS和WFC组之间的GA，IM和异型增生程度无统计学差异。模型组幽门螺杆菌感染率（阳性/阴性：9/1）明显高于对照组（阳性/阴性：1/9）（P <0.01）。大剂量WAS组（阳性/阴性：4/6）和小剂量WAS组（阳性/阴性：6/4）的H幽门螺杆菌消除与WFC组（阳性/阴性：4/6）相似）（P> 0.05）。结论：WAS通过抑制GA，IM和发育异常并消除幽门螺杆菌改善了临床症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号